AcquisitionsApr 30, 2026, 04:48 PM
HURA Amends Pro Forma Financials for Kineta Acquisition
AI Summary
TuHURA Biosciences, Inc. filed an amendment to its prior Form 8-K to correct errors in the unaudited pro forma condensed combined financial statements for the year ended December 31, 2025. These statements reflect the completed acquisition of Kineta, Inc. on June 30, 2025, as if it occurred on January 1, 2025. The pro forma net loss for the year was $(34,469,964), resulting in a net loss per share of $(0.66). The acquisition had an estimated purchase price of $16,560,163, including significant in-process research and development and goodwill. Additionally, the company completed a private placement in June 2025, raising $11,512,169 in net proceeds.
Key Highlights
- HURA filed an amendment to correct errors in its unaudited pro forma condensed combined financial statements for the Kineta acquisition.
- The Kineta acquisition was completed on June 30, 2025, with TuHURA as the accounting acquirer.
- Pro forma net loss for the year ended December 31, 2025, was $(34,469,964).
- Pro forma net loss per share, basic and diluted, for 2025 was $(0.66).
- Total estimated purchase price for the Kineta acquisition was $16,560,163.
- Identifiable intangible assets for in-process R&D acquired were $11,275,000, with $10,738,082 in goodwill.
- A June 2025 private placement raised $11,512,169 in net proceeds from issuing 4,759,309 shares and warrants.